Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Selects GenoLogics' LIMS Software to Support HiSeq Customers

NEW YORK (GenomeWeb) – GenoLogics said today that Illumina has selected its Clarity laboratory information management system (LIMS) as the preferred software for customers of its HiSeq X Ten sequencing platform.

With this announcement, GenoLogics makes good on a promise it made earlier this year that an upcoming release of Clarity would include support for the HiSeq X Ten. Together, the companies are currently working on support for HiSeq X Ten whole-genome workflows and analysis pipelines, including those that will be used inside of Illumina, GenoLogics said. Additionally, Illumina will use Clarity to support its collaboration with Genomics England to sequence 100,000 genomes.

"Illumina is pleased to be working with GenoLogics to ensure HiSeq X Ten customers receive the LIMS support they need," Alex Dickinson, Illumina's senior vice president of strategic initiatives, said in a statement. "Scaling a lab to deliver the $1,000 genome presents unique challenges and GenoLogics has the demonstrated ability and understanding of our technologies to support these labs."

GenoLogics' Clarity already supports Illumina's TruSight individual genome sequencing test as well as its HiSeq, MiSeq, and Genome Analyzer sequencers.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more